July 14, 2022 02:41 PM EDTUpdated July 15, 03:43 PM
Deals
Pharma

Bay­er sells testos­terone treat­ment to Ger­man com­pa­ny for $500M

Aayushi Pratap

News Reporter

Bay­er AG is all set to sell its testos­terone de­fi­cien­cy treat­ment Nebido to Grü­nen­thal, a Ger­man pain man­age­ment com­pa­ny for about $500 mil­lion.

The deal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times